Physician profile
Ashley Jackson
NPI 1124265459
$1,680.83
in general payments reported to CMS, 2019-2025
14 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.35 · 2022: $406 · 2023: $473 · 2024: $428 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $466.20 | 2022-2023 | Xarelto |
| Pfizer INC. | $356.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $329.12 | 2022-2025 | Dificid, Verquvo, Zerbaxa |
| Abbvie INC. | $186.06 | 2025 | |
| Alexion Pharmaceuticals, INC. | $75.49 | 2022-2024 | Ultomiris |
| Vertex Pharmaceuticals Incorporated | $44.87 | 2024-2025 | |
| Shionogi INC | $40.23 | 2023-2024 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.86 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $33.18 | 2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.48 | 2022 | |
| Lilly USA, LLC | $27.29 | 2023 | Jardiance |
| Tersera Therapeutics LLC | $22.83 | 2025 | Xermelo |
| Pharmacosmos Therapeutics INC. | $18.70 | 2025 | Monoferric |
| Iovance Biotherapeutics, INC. | $17.84 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.